A number of firms have modified their ratings and price targets on shares of Jazz Pharmaceuticals PLC (NASDAQ: JAZZ) recently:

  • 9/28/2017 – Jazz Pharmaceuticals PLC is now covered by analysts at Goldman Sachs Group, Inc. (The). They set a “neutral” rating and a $165.00 price target on the stock.
  • 9/25/2017 – Jazz Pharmaceuticals PLC had its “buy” rating reaffirmed by analysts at UBS AG. They now have a $172.00 price target on the stock, down previously from $175.00.
  • 9/20/2017 – Jazz Pharmaceuticals PLC had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $196.00 price target on the stock.
  • 9/18/2017 – Jazz Pharmaceuticals PLC had its “buy” rating reaffirmed by analysts at J P Morgan Chase & Co. They now have a $190.00 price target on the stock.
  • 9/15/2017 – Jazz Pharmaceuticals PLC had its “buy” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $210.00 price target on the stock.
  • 8/30/2017 – Jazz Pharmaceuticals PLC had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $190.00 price target on the stock.
  • 8/29/2017 – Jazz Pharmaceuticals PLC had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald.
  • 8/29/2017 – Jazz Pharmaceuticals PLC had its “buy” rating reaffirmed by analysts at Wells Fargo & Company.
  • 8/25/2017 – Jazz Pharmaceuticals PLC is now covered by analysts at HC Wainwright. They set a “neutral” rating and a $144.00 price target on the stock.
  • 8/21/2017 – Jazz Pharmaceuticals PLC was given a new $190.00 price target on by analysts at Cowen and Company. They now have a “buy” rating on the stock.
  • 8/10/2017 – Jazz Pharmaceuticals PLC had its “outperform” rating reaffirmed by analysts at Wells Fargo & Company. They now have a $177.00 price target on the stock, down previously from $178.00.
  • 8/10/2017 – Jazz Pharmaceuticals PLC had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $177.00 price target on the stock.
  • 8/9/2017 – Jazz Pharmaceuticals PLC had its “buy” rating reaffirmed by analysts at Janney Montgomery Scott. They now have a $192.00 price target on the stock, up previously from $180.00.
  • 8/9/2017 – Jazz Pharmaceuticals PLC had its “buy” rating reaffirmed by analysts at Royal Bank Of Canada.
  • 8/9/2017 – Jazz Pharmaceuticals PLC was given a new $175.00 price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock.
  • 8/9/2017 – Jazz Pharmaceuticals PLC had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $190.00 price target on the stock.
  • 8/8/2017 – Jazz Pharmaceuticals PLC was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $174.00 price target on the stock. According to Zacks, “Jazz’s largest franchise is its sleep disorder portfolio. The company’s sleep disorder drug, Xyrem, is the only FDA-approved product for both cataplexy and EDS. Its lead pipeline candidate, JZP-110, being developed for the treatment of EDS in patients suffering from narcolepsy and OSA, complements its existing sleep disorder portfolio. Moreover, In Oct 2016, Jazz commenced a rolling submission for its second pipeline candidate, Vyxeos, which was completed in early Apr 2017. Jazz’ shares outperformed the industry so far this year. However, Xyrem is facing patent challenges. Jazz has also been facing challenges in building sufficient inventory levels for leukemia drug Erwinaze due to constrained manufacturing capacity and may experience further supply disruptions this year. Estimates have been stable lately ahead of the company’s Q2 earnings release.”

Jazz Pharmaceuticals PLC (NASDAQ JAZZ) opened at 149.61 on Wednesday. The stock has a market cap of $8.99 billion, a PE ratio of 23.05 and a beta of 1.05. Jazz Pharmaceuticals PLC has a 1-year low of $95.80 and a 1-year high of $163.75. The stock has a 50 day moving average price of $148.60 and a 200 day moving average price of $151.49.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last posted its earnings results on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 EPS for the quarter, missing the Zacks’ consensus estimate of $1.85 by ($0.13). The firm had revenue of $394.39 million for the quarter, compared to analysts’ expectations of $410.83 million. Jazz Pharmaceuticals PLC had a net margin of 25.69% and a return on equity of 22.75%. The company’s revenue was up 3.5% on a year-over-year basis. During the same period in the previous year, the company earned $2.67 EPS. On average, analysts predict that Jazz Pharmaceuticals PLC will post $10.88 EPS for the current fiscal year.

In other news, CEO Bruce C. Cozadd sold 1,000 shares of the stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $153.52, for a total transaction of $153,520.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael Patrick Miller sold 200 shares of the stock in a transaction on Monday, July 17th. The shares were sold at an average price of $154.97, for a total value of $30,994.00. The disclosure for this sale can be found here. Insiders sold 8,297 shares of company stock worth $1,279,417 over the last ninety days. Corporate insiders own 4.30% of the company’s stock.

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with MarketBeat.com's FREE daily email newsletter.